Recent data indicate that in ECs, treatment with GLP-1 agonists prevented high glucose-induced demethylation in the promoter region of nuclear factor-kB (NF-kB) and superoxide dismutase 2 (SOD2), avoiding their detrimental expression, suggesting a potential role of GLP-1 and GLP-1R agonists on epigenetic machinery to prevent the vascular diabetic complications. The gene discussed is SOD2; the disease is diabetes mellitus.